Erika Hamilton, Chief Development Officer, Late Phase and Director, Breast Cancer Research Program at Sarah Cannon Research Institute, shared on X:
“Plain language summary of H2C05!
Treatment outcomes of tucatinib in combination with trastuzumab and pertuzumab as a maintenance therapy for people with HER2+ MBC: a plain language summary of findings from HER2CLIMB-05: Future Oncology: Vol 0, No 0.”
Title: Treatment outcomes of tucatinib in combination with trastuzumab and pertuzumab as a maintenance therapy for people with HER2+ metastatic breast cancer: a plain language summary of findings from HER2CLIMB-05
Authors: Veronique Dieras, Giuseppe Curigliano, Miguel Martin, Florence Lerebours, Junji Tsurutani, Marie-France Savard, Katarzyna J. Jerzak, Xichun Hu, Luciana Carla Martins de Aquino Pimentel, Ciara C. O’Sullivan, Eriko Tokunaga, Alicia Okines, Chiun-Sheng Huang, William Jacot, Joohyuk Sohn, Eduardo Cronemberger Silva, Volkmar Muelle, Shan Yang, Giovanna Granata, Qi Shen, Erika Hamilton
You can also read: DESTINY-Breast09 Redefines First-Line HER2-Positive Breast Cancer: Balancing Efficacy, Safety, and Treatment Selection.
